BiotechTube
Brenig Therapeutics

Brenig Therapeutics

Cambridge, United States· Est.
brenigther.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $69M

Overview

Brenig Therapeutics is a private, preclinical-stage biotech founded in 2021 by a consortium of leading life science investors. The company is developing a pipeline of brain-penetrant small molecules, led by BT-267, a selective LRRK2 inhibitor for Parkinson's disease that has completed a Phase 1 study. Brenig leverages AI and machine learning in its drug discovery process to design highly selective compounds with optimized CNS exposure, aiming to build a portfolio of first- and best-in-class therapies for neurodegenerative disorders.

Neurodegenerative DiseasesParkinson's Disease

Technology Platform

AI and machine learning-enhanced drug discovery platform for designing selective, brain-penetrant small molecules.

Funding History

2
Total raised:$69M
PIPE$65M
Seed$4M

Opportunities

The vast, unmet need for disease-modifying therapies in Parkinson's disease and other neurodegenerative disorders represents a multi-billion dollar market.
Brenig's targeted approach with potentially best-in-class, brain-penetrant molecules for validated targets (LRRK2, NLRP3) could capture significant value in specific patient subsets and across broader indications driven by neuroinflammation.

Risk Factors

High clinical development risk, as efficacy in modifying neurodegenerative disease progression is unproven for its candidates.
Intense competition in both the LRRK2 and NLRP3 inhibitor spaces from better-funded entities.
Dependence on venture financing and potential challenges in raising future capital to fund expensive late-stage trials.

Competitive Landscape

Brenig faces competition in the LRRK2 space from companies like Denali Therapeutics (with Biogen) and Genentech, and in the NLRP3 space from numerous biopharma players. Its differentiation is based on a molecule design focused on maximizing brain penetration and minimizing peripheral exposure, aiming for a best-in-class profile.

More companies in Small Molecule Drugs →More companies in United States →